Rapamycin is by far the world’s leading candidate for an effective and accessible anti-aging drug. Nothing else comes close. If you’re interested in a longer, healthier life, you probably want to consider taking rapamycin or at least keep a close eye on the research going forward.
Rapamycin is considered by many geroscience researchers to be the “gold standard” of anti-aging drugs for some very good reasons:
Its been shown to be very effective in every species its been tested in, from yeast, to worms, to flies, to mice. Rapamycin is now in ongoing, longterm testing in healthy monkeys and dogs with success reported to date.
The lifespan improvement seen in animal trials are the most consistent and highest of any drug (typically 9% to 30% in mouse studies). Dozens of independent studies report lifespan and age-related health benefits from rapamycin in mice, including reversal of deficits in multiple tissues. At least two studies show big effects from transient treatments during middle-age.
In addition to lifespan, the things rapamycin improves in aging mice are: cancers (better outcomes), cognitive function, heart, immune, kidney, oral health, intestine/gut dysbiosis, tendon, liver, auditory function, ovary, stem cells, spinal discs…
Rapamycin’s efficacy has been validated by many different independent research groups around the world.
Rapamycin is FDA approved (albeit at high doses for cancer and transplant patients), and has been used in millions of patients over the past 20 years.
Because rapamycin is off-patent, and now available as a generic medicine it can be very affordable, or even inexpensive.
Doctors have started to prescribe rapamycin for anti-aging, and thousands of people are already using it.
The key issue with rapamycin is that there currently is no clear pathway to approval by the FDA for an anti-aging drug, and no commercial entity wants to fund large human clinical studies for rapamycin because its already a cheap generic drug and companies can’t make money off it. Small human clinical studies are in process, but these small clinical trials will take years, and even then likely won’t satisfy the FDA (a typical phase 3 clinical trial has 3,000 patients enrolled, the rapamycin human clinical studies planned today only have 20 to 150 people). Additionally, the FDA has little history in area of drugs for prevention (though statins may be a counter-example to that). So rapamycin may continue to be overlooked by the medical establishment for many decades going forward.
Thousands of people around the world have already decided that the evidence is compelling enough and they don’t want to wait years (or decades) for a large-scale, human clinical trial to finally be funded and completed. These people have shared the research data we cover on this website with their doctor (or found a doctor - see our list), and gotten a prescription for rapamycin, and are following a low-dose, intermittent/pulsed dosing protocol with some success.
Read the full story about rapamycin and make your own decision.
The full story: Why take Rapamycin? (part 2)